Upstream Bio
UPB6.5702.50% ( +0.160 )
Upstream Bio (UPB)
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers ve...
- Open
- 6.350
- High
- 6.665
- Low
- 6.290
- Prev. Close
- 6.410
- Volume
- 320.62K
- Turnover
- 2.10M
- Avg Price
- 6.540
- Bid/Ask Ratio
- --
- Amplitude
- 5.85%
- 52wk High
- 33.680
- Volume Ratio
- 0.39
- Turnover Ratio
- 0.79%
Upstream Bio Analyst Rating
View MoreForecast & Rating
Jun 25, 2026Price forecast
$38.25482.19%
Forecast & RatingBuy
9analysts
- Strong buy66.67%
- Buy11.11%
- Hold22.22%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 13 hours ago
The Misfit Toys of 2026: From Quantum Dreams to Chicken Wings
- Global Report · 1 day ago, 04:19 AM
Beyond the Mega-Caps: Surviving the Market's Uncategorized Fringe
- Global Report · Jul 26 at 04:15 AM
Biotech Regulatory Clearances and Edge AI Pivots Prompt Capital Reallocation Across US Equities
- Global Report · Jul 25 at 04:17 AM
Inside the Biotech Sector's Recent Clinical Catalyst Wave
- Global Report · Jul 25 at 04:13 AM
Flying Cars, Defense Pivots, and the Tech Fringe of 2026
- Global Report · Jul 24 at 04:13 AM
The 2026 Biotech Divide: When Generative Biology Meets the FDA Wall
